Caristo Congratulates Abcentra for First Patient Dosed Successfully in Phase 2b 'FORTIFY' Clinical Trial Evaluating Orticumab in Patients with Cardiovascular Disease

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

CARISTO-DIAGNOSTICS

More Like This

PR Newswire associated0

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

PR Newswire associated0

Caristo to Unveil New Clinical and Research Results at SCCT 2025

PR Newswire associated0

Caristo Secures FDA Clearance, Ushering in a New Era of AI-Powered Heart Attack Prevention

PR Newswire associated0

The Lancet Publishes Results from World's Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance

PR Newswire associated0

Agepha Pharma and Caristo Diagnostics Team Up to Fight Coronary Inflammation

PR Newswire associated0

European Society of Cardiology (ESC) Congress 2025 Late Breaking Results Confirm Caristo FAI-Score™ Technology's Superior and Complementary Predictive Value for Cardiac Death Beyond hsCRP

PR Newswire associated0

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

PR Newswire associated0

Caristo Diagnostics Recognized as Quarterfinalist in the Digital Health Awards, Rising Star Category